SG11201510699WA - Antitubercular composition comprising rifampicin, isoniazid, ethambutol and pyrazinamide and its process of preparation. - Google Patents
Antitubercular composition comprising rifampicin, isoniazid, ethambutol and pyrazinamide and its process of preparation.Info
- Publication number
- SG11201510699WA SG11201510699WA SG11201510699WA SG11201510699WA SG11201510699WA SG 11201510699W A SG11201510699W A SG 11201510699WA SG 11201510699W A SG11201510699W A SG 11201510699WA SG 11201510699W A SG11201510699W A SG 11201510699WA SG 11201510699W A SG11201510699W A SG 11201510699WA
- Authority
- SG
- Singapore
- Prior art keywords
- pyrazinamide
- ethambutol
- isoniazid
- rifampicin
- preparation
- Prior art date
Links
- AEUTYOVWOVBAKS-UWVGGRQHSA-N ethambutol Chemical compound CC[C@@H](CO)NCCN[C@@H](CC)CO AEUTYOVWOVBAKS-UWVGGRQHSA-N 0.000 title 2
- 230000002365 anti-tubercular Effects 0.000 title 1
- 229960000285 ethambutol Drugs 0.000 title 1
- 229960003350 isoniazid Drugs 0.000 title 1
- QRXWMOHMRWLFEY-UHFFFAOYSA-N isoniazide Chemical compound NNC(=O)C1=CC=NC=C1 QRXWMOHMRWLFEY-UHFFFAOYSA-N 0.000 title 1
- 229960005206 pyrazinamide Drugs 0.000 title 1
- IPEHBUMCGVEMRF-UHFFFAOYSA-N pyrazinecarboxamide Chemical compound NC(=O)C1=CN=CC=N1 IPEHBUMCGVEMRF-UHFFFAOYSA-N 0.000 title 1
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 title 1
- 229960001225 rifampicin Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/133—Amines having hydroxy groups, e.g. sphingosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
- A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN3343CH2013 | 2013-07-26 | ||
| PCT/EP2014/065763 WO2015011163A1 (en) | 2013-07-26 | 2014-07-22 | Antitubercular composition comprising rifampicin, isoniazid, ethambutol and pyrazinamide and its process of preparation. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201510699WA true SG11201510699WA (en) | 2016-01-28 |
Family
ID=51212860
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201510699WA SG11201510699WA (en) | 2013-07-26 | 2014-07-22 | Antitubercular composition comprising rifampicin, isoniazid, ethambutol and pyrazinamide and its process of preparation. |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US9814711B2 (en) |
| EP (1) | EP3024445B1 (en) |
| JP (1) | JP2017501117A (en) |
| CN (1) | CN105407874A (en) |
| AU (1) | AU2014295100B2 (en) |
| CA (1) | CA2918828A1 (en) |
| CL (1) | CL2016000180A1 (en) |
| HK (1) | HK1218721A1 (en) |
| IL (1) | IL243370A0 (en) |
| MX (1) | MX2016001156A (en) |
| MY (1) | MY174007A (en) |
| PE (1) | PE20160238A1 (en) |
| PH (1) | PH12016500118A1 (en) |
| RU (1) | RU2672879C2 (en) |
| SG (1) | SG11201510699WA (en) |
| TW (1) | TW201601716A (en) |
| WO (1) | WO2015011163A1 (en) |
| ZA (1) | ZA201600108B (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2016001155A (en) | 2013-07-26 | 2016-04-29 | Sanofi Sa | Anti-tuberculosis stable pharmaceutical composition in a form of a dispersible tablet comprising granules of isoniazid and granules of rifapentine and its process of preparation. |
| KR20180126511A (en) * | 2016-04-08 | 2018-11-27 | 큐어테크 바이오 에이비 | Ring-fused thiazolidino-2-pyridone, its preparation and its use in the treatment and / or prevention of tuberculosis |
| EP3691619A1 (en) * | 2017-10-05 | 2020-08-12 | Quretech Bio AB | Ring-fused thiazolino 2-pyridones in combination with a drug against tuberculosis |
| WO2019162964A1 (en) * | 2018-02-23 | 2019-08-29 | Indian Institute Of Science | Anti-tubercular composition, and combinatorial implementations thereof |
| CN108186638A (en) * | 2018-03-08 | 2018-06-22 | 重庆华邦制药有限公司 | The pharmaceutical composition of isoniazid |
| AU2022405079A1 (en) * | 2021-12-07 | 2024-06-27 | An2 Therapeutics, Inc. | Combinations |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1217912A (en) | 1997-11-26 | 1999-06-02 | 岑冠新 | Compound rifapentine preparation and preparation method thereof |
| NZ518216A (en) * | 2000-08-09 | 2004-11-26 | Panacea Biotec Ltd | Pharmaceutical compositions of anti-tubercular drugs and process for their preparation |
| WO2002087547A1 (en) | 2001-04-27 | 2002-11-07 | Lupin Limited | An improved process for preparation of four-drug anti-tubercular fixed dose combination |
| RU2195937C1 (en) * | 2002-02-06 | 2003-01-10 | НИИ молекулярной медицины ММА им. И.М.Сеченова | Combined antituberculosis preparation (rizobutol) |
| US20050059719A1 (en) | 2003-09-16 | 2005-03-17 | Badawy Sherif Ibrahim Farag | Solid dosage formulation containing a Factor Xa inhibitor and method |
| EP1711182A1 (en) * | 2004-02-04 | 2006-10-18 | Vinay Ramakant Sapte | Oral cyclodextrin complexes of antituberculosis drugs |
| TWI368509B (en) | 2005-10-05 | 2012-07-21 | Otsuka Pharma Co Ltd | Antituberculous therapeutic drugs and kit containing the same |
| CN1989966B (en) | 2005-12-30 | 2011-06-08 | 重庆华邦制药股份有限公司 | Pharmaceutical composition comprising rifamoin and isoniazid |
| CN1857280A (en) | 2006-04-11 | 2006-11-08 | 济南帅华医药科技有限公司 | Slow released compound antituberculotic preparation |
| KR101197277B1 (en) | 2009-02-05 | 2012-11-05 | (주) 벡스코아 | Oral Solid Preparation For Treatment And Prevention Of Tuberculosis |
| AP2012006119A0 (en) | 2009-07-31 | 2012-02-29 | Cadila Pharmaceuticals Ltd | Pharmaceutical composition of isoniazid. |
| WO2012013756A2 (en) * | 2010-07-28 | 2012-02-02 | Laboratoires Pharma 5 | Method for preparing tablets combining rifampicin, isoniazid, pyrazinamide and, optionally, ethambutol |
| US8470365B2 (en) * | 2010-07-29 | 2013-06-25 | Taiwan Biotech Co., Ltd. | Process for preparation of anti-tubercular combination and pharmaceutical composition prepared therefrom |
| MX2016001155A (en) | 2013-07-26 | 2016-04-29 | Sanofi Sa | Anti-tuberculosis stable pharmaceutical composition in a form of a dispersible tablet comprising granules of isoniazid and granules of rifapentine and its process of preparation. |
| RU2682178C2 (en) | 2013-07-26 | 2019-03-15 | Санофи | Anti-tuberculosis stable pharmaceutical composition in a form of a coated tablet comprising granules of isoniazid and granules of rifapentine and its process of preparation |
-
2014
- 2014-07-22 RU RU2016106336A patent/RU2672879C2/en not_active IP Right Cessation
- 2014-07-22 PE PE2016000091A patent/PE20160238A1/en unknown
- 2014-07-22 CN CN201480041951.1A patent/CN105407874A/en active Pending
- 2014-07-22 CA CA2918828A patent/CA2918828A1/en not_active Abandoned
- 2014-07-22 MY MYPI2015704808A patent/MY174007A/en unknown
- 2014-07-22 WO PCT/EP2014/065763 patent/WO2015011163A1/en active Application Filing
- 2014-07-22 JP JP2016528511A patent/JP2017501117A/en not_active Ceased
- 2014-07-22 EP EP14741897.4A patent/EP3024445B1/en not_active Not-in-force
- 2014-07-22 SG SG11201510699WA patent/SG11201510699WA/en unknown
- 2014-07-22 AU AU2014295100A patent/AU2014295100B2/en not_active Expired - Fee Related
- 2014-07-22 MX MX2016001156A patent/MX2016001156A/en unknown
- 2014-07-22 US US14/906,870 patent/US9814711B2/en not_active Expired - Fee Related
- 2014-07-25 TW TW103125583A patent/TW201601716A/en unknown
-
2015
- 2015-12-28 IL IL243370A patent/IL243370A0/en unknown
-
2016
- 2016-01-06 ZA ZA2016/00108A patent/ZA201600108B/en unknown
- 2016-01-19 PH PH12016500118A patent/PH12016500118A1/en unknown
- 2016-01-22 CL CL2016000180A patent/CL2016000180A1/en unknown
- 2016-06-14 HK HK16106815.2A patent/HK1218721A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3024445B1 (en) | 2019-01-09 |
| MX2016001156A (en) | 2016-04-29 |
| CA2918828A1 (en) | 2015-01-29 |
| WO2015011163A1 (en) | 2015-01-29 |
| PH12016500118A1 (en) | 2016-04-25 |
| IL243370A0 (en) | 2016-02-29 |
| RU2672879C2 (en) | 2018-11-20 |
| AU2014295100B2 (en) | 2019-01-03 |
| HK1218721A1 (en) | 2017-03-10 |
| US9814711B2 (en) | 2017-11-14 |
| JP2017501117A (en) | 2017-01-12 |
| CN105407874A (en) | 2016-03-16 |
| MY174007A (en) | 2020-03-03 |
| AU2014295100A1 (en) | 2016-02-11 |
| RU2016106336A3 (en) | 2018-05-17 |
| EP3024445A1 (en) | 2016-06-01 |
| RU2016106336A (en) | 2017-08-31 |
| CL2016000180A1 (en) | 2016-06-24 |
| US20160158226A1 (en) | 2016-06-09 |
| ZA201600108B (en) | 2017-04-26 |
| TW201601716A (en) | 2016-01-16 |
| PE20160238A1 (en) | 2016-05-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1218721A1 (en) | Antitubercular composition comprising rifampicin, isoniazid, ethambutol and pyrazinamide and its process of preparation | |
| PL3206756T3 (en) | Use of hexadeca-8,15-dienal as an aroma chemical | |
| HK1212207A1 (en) | Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith | |
| IL277069B (en) | Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith | |
| EP3169326A4 (en) | Suppression of myeloid derived suppressor cells and immune checkpoint blockade | |
| IL246252A0 (en) | Substituted diaminopyrimidyl compounds, compositions thereof, and methods of treatment therewith | |
| EP3389663A4 (en) | Pyrrolopyrimidine compounds, use as inhibitors of the kinase lrrk2, and methods for preparation thereof | |
| HK1248070A1 (en) | Heterocyclic compounds as kinase inhbitors | |
| EP2957615A4 (en) | Composition for forming water-repellent films, and use of same | |
| WO2014165090A8 (en) | Compounds for the treatment of tuberculosis | |
| EP3115361A4 (en) | Heterocyclic compounds, and preparation method and use thereof | |
| HK1232291A1 (en) | Substrates and methods for collection, stabilization and elution of biomolecules | |
| IL253204B (en) | Trifluoroacetyl hydrazide compounds and methods of preparation and uses thereof | |
| PL3157388T3 (en) | Rotatable piece of seating furniture | |
| GB201820612D0 (en) | (Fingerprint) powder composition | |
| RO130539B8 (en) | Herbicidal composition, preparation process and use thereof | |
| EP3089745A4 (en) | Compounds, compositions, and methods for the treatment of cancers | |
| EP3195851A4 (en) | Composition containing meso-2,3-butanediol | |
| EP3241543A4 (en) | Chemically anisotropic powder, and cosmetic composition containing same | |
| EP3226886A4 (en) | Use of fibulin-5 for the treatment of keloid scars | |
| HK1258042A1 (en) | Tea leaf powder | |
| EP2969579A4 (en) | Treated ammonium octamolybdate composition | |
| IL243133B (en) | Method for the preparation of (1,2,4)-triazolo(4,3-a)pyridines | |
| ZA201404780B (en) | Composition for use in treatment of diabetes | |
| GB201401598D0 (en) | Cells, preparation, uses, methods and components |